Bioequivalence study of GP-IMP-001 with regards to reference product

2024-515889-14-00 Protocol Gebro-I-56.1 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 22 Jan 2025 · End 26 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol Gebro-I-56.1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 24
Countries 1
Sites 1

healthy volunteers

Key facts

Sponsor
Gebro Pharma GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Not possible to specify
Trial duration
22 Jan 2025 → 26 Feb 2025
Decision date (initial)
2024-12-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

healthy volunteers

VersionLevelCodeTermSystem organ class
23.1 LLT 10003268 Arthritis rheumatoid 10028395
20.0 LLT 10011402 Crohn's disease (colon) 10017947
27.0 LLT 10090623 Generalized pustular psoriasis 100000004858

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Gebro Pharma GmbH

Sponsor organisation
Gebro Pharma GmbH
Address
Bahnhofbichl 13
City
Fieberbrunn
Postcode
6391
Country
Austria

Scientific contact point

Organisation
Gebro Pharma GmbH
Contact name
clinical department

Public contact point

Organisation
Gebro Pharma GmbH
Contact name
clinical department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 24 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Cepha s.r.o.
clinic, Komenskeho 19, Severni Predmesti, Plzen 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-01-22 2025-02-26 2025-01-22 2025-01-31

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-27 Czechia Acceptable
2024-12-19
2024-12-19
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-01-10 Czechia Acceptable
2024-12-19
2025-01-10